Prenatal Sterol-Inhibiting Drugs Linked to Increased Autism Risk

The mevalonate and cholesterol biosynthetic pathways are fundamental to the structural and functional development of the central nervous system, serving as essential components for synaptogenesis (the formation of synapses between neurons) and myelin formation [1]. While genetic mutations in these pathways are known to cause severe neurologic and psychiatric phenotypes, there is growing concern regarding the impact of exogenous chemical interference during critical gestational windows [2]. Sterol metabolism is increasingly recognized as a biological factor in the pathogenesis of neurodevelopmental conditions, including autism spectrum disorders [3]. Despite this, many common medications used to treat cardiovascular and psychiatric conditions act by inhibiting post-lanosterol biosynthesis (the enzymatic steps that convert lanosterol into cholesterol), often without established safety guidelines for use during pregnancy [2]. Emerging metabolomic evidence from animal models further suggests that disrupted steroid hormone and cholesterol pathways in the hippocampus, a region critical for memory and social behavior, correlate with autistic-like behavioral traits [4]. A large-scale clinical analysis now provides critical data on how these common pharmacological exposures may influence neurodevelopmental outcomes in humans.